Ondine Biomedical (LON:OBI) Trading Up 1.7% - What's Next?

Key Points

• Ondine Biomedical's stock price increased by 1.7% to close at C$15.25, following a trading volume surge of 280% from its average daily volume.
• The company boasts a market capitalization of C$6.77 billion and a debt-to-equity ratio of 25.95.
• Ondine Biomedical focuses on innovative photodisinfection-based therapies aimed at preventing and treating infections caused by various pathogens, including antimicrobial-resistant ones.

Ondine Biomedical Inc. (LON:OBI - )'s stock price rose 1.7% during trading on Friday . The company traded as high as C$15.50 and last traded at C$15.25. Approximately 1,201,245 shares were traded during mid-day trading, an increase of 280% from the average daily volume of 316,169 shares. The stock had previously closed at C$15.00.

Ondine Biomedical Stock Performance

The stock's 50 day moving average price is C$14.38 and its 200 day moving average price is C$11.50. The company has a debt-to-equity ratio of 25.95, a quick ratio of 8.26 and a current ratio of 1.36. The company has a market capitalization of C$6.77 billion, a P/E ratio of -217.86 and a beta of 0.10.

About Ondine Biomedical

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens. Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.